New technologies and production lines at BTG Israel plant will support the development of new treatments in reproductive medicine and women’s health. Ferring Pharmaceuticals announced today that it is investing $15 million to expand biotech production capabilities at its Israeli subsidiary Bio-Technology General (BTG). Over the next three years, Ferring will incorporate new production lines and innovative technologies at the BTG facility in the Beer Tuvia’s industrial park south of Tel Aviv. These technologies will support the development of new treatments in reproductive medicine and women’s health, in addition to the manufacturing of the active pharmaceutical ingredient (API) for Rekovelle (follitropin delta), Ferring’s latest fertility treatment. Ferring SVP manufacturing Hervé Udriot said, “Ferring is committed to investing in innovative technology platforms to create new solutions for patients in our core area of reproductive medicine and women’s health. BTG is already helping people around the world to build families through the development of our latest fertility treatment. This significant investment will allow us to maintain our scientific leadership in the fertility field.”
